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ISSOBJECTIVES To assess whether single-photon emission computed tomography (SPECT/CT) quantification of bone
scintigraphy would improve diagnostic accuracy and offer a means of quantifying amyloid burden.
BACKGROUND Transthyretin-related cardiac amyloidosis is common and can be diagnosed noninvasively using
bone scintigraphy; interpretation, however, relies on planar images. SPECT/CT imaging offers 3-dimensional visualization.
METHODS This was a single-center, retrospective analysis of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD)
scans reported using the Perugini grading system (0 ¼ negative; 1 to 3 ¼ increasingly positive). Conventional planar quantifi-
cation techniques (heart/contralateral lung, and heart/whole-body retention ratios) were performed. Heart, adjacent vertebra,
paraspinal muscle and liver peak standardized uptake values (SUVpeak) were recorded from SPECT/CT acquisitions. An SUV
retention index was also calculated: (cardiac SUVpeak/vertebral SUVpeak)  paraspinal muscle SUVpeak. In a subgroup of patients,
SPECT/CT quantification was compared with myocardial extracellular volume quantification by CT imaging (ECVCT).
RESULTS A total of 100 DPD scans were analyzed (patient age 84 9 years; 52%male): 40were Perugini grade 0, 12 were
grade 1,41weregrade2, and7weregrade3. Cardiac SUVpeak increased fromgrade0 tograde2;however, it plateauedbetween
grades 2 and 3 (p<0.001). Paraspinalmuscle SUVpeak increasedwith grade (p<0.001), whereas vertebral SUVpeak decreased
(p< 0.001). The composite parameter of SUV retention index overcame the plateauing of the cardiac SUVpeak and increased
across all grades (p< 0.001). Cardiac SUVpeak correlatedwell (r2¼0.73; p<0.001)with ECVCT. Both the cardiac SUVpeak and
SUV retention index had excellent diagnostic accuracy (area under the curve [AUC]: 0.999). The heart to contralateral lung
ratio performed the best of the planar quantification techniques (AUC: 0.987).
CONCLUSIONS SPECT/CT quantification in DPD scintigraphy is possible and outperforms planar quantification
techniques. Differentiation of Perugini grade 2 or 3 is confounded by soft tissue uptake, which can be overcome by
a composite SUV retention index. This index can help in the diagnosis of cardiac amyloidosis and may offer a means
of monitoring response to therapy. (J Am Coll Cardiol Img 2020;13:1353–63) © 2020 The Authors. Published by Elsevier
on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY license
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ABBR EV I A T I ON S
AND ACRONYMS
AL = amyloidosis, primary
light-chain amyloidosis
ATTR = transthyretin-related
amyloidosis
ATTR-CA = transthyretin-
related cardiac amyloidosis
CI = confidence interval
CT = computed tomography
DPD = 99mTc-3,3-diphosphono-
1,2-propanodicarboxylic acid
ECVCT = extracellular volume
quantification by computed
tomography
H/CL ratio = heart to
contralateral lung ratio
PYP = 99mTc-pyrophosphate
ROI = region of interest
SPECT = single-photon
emission computed
tomography
SUV = standardized uptake
value
VOI = volume of interest
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1354A myloidosis is a multisystem condi-tion characterized by the extracellulardeposition of abnormally folded pro-
tein fibrils, which result in progressive organ
dysfunction (1). Primary light chain (AL) and
transthyretin-related amyloidosis (ATTR)
commonly affect the heart; the latter can
either be associated with a TTR gene mutation
(variant ATTR) or not (wild-type ATTR).
Previously believed to be rare, more recent
research has identified cardiac ATTR (ATTR-
CA) in a significant proportion (14% to 16%) of
elderly patients with aortic stenosis (2,3),
as well as in 13% of the population with heart
failure with preserved ejection fraction (4).
A primary driver of this realization is
the development of noninvasive diagnostic
techniques, which reduce the need for
endomyocardial biopsy in an often frail and
comorbid population. A key technique in
this regard is bone scintigraphy (99mTc-3,
3-diphosphono-1,2-propanodicarboxylic acid
[DPD], 99mTc-pyrophosphate [PYP], and
99mTc-hydroxymethylene diphosphonate),which, coupled with the exclusion of plasma cell
dyscrasia, now offer a noninvasive diagnosis for
ATTR-CA (5).
DPD scintigraphy is currently reported by using the
Perugini grading system, which is a visual score of the
delayed (3-h) planar image, graded from0 (negative) to
3 (strongly positive) (6). This grading system offers
little prognostic significance (7). Difficulty can also
ensue in differentiating very subtle cardiac uptake
(i.e., a Perugini grade 1) from a negative scanwith some
residual blood pool activity, despite the additional use
of single-photon emission computed tomography
(SPECT) imaging. The clinical importance of this
distinction remains to be determined; however, it mayiNational Amyloidosis Centre, University College London, Londo
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FIGURE 1 SPECT/CT and H/CL Ratio Quantification
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Fused axial single-photon emission computed tomography/computed tomography (SPECT/CT) 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid images demon-
strating volume of interest (VOI) (green) positioning for standardized uptake value (SUV) quantification on the left. The small green square within each VOI represents
the peak SUV (SUVpeak), which enables the reporter to ensure that the recorded SUVpeak lies within the desired organ/tissue. On the right, 3-h planar, whole-body
99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid image of a different patient with regions of interest over the heart (1) and contralateral lung (4). H/CL ¼ heart/
contralateral lung.
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This work forms part of ATTRact-AS (A Study Inves-
tigating the Role of Occult Cardiac Amyloid in the
Elderly With Aortic Stenosis; NCT03029026). The
relevant local ethics (London–City Road and Hamp-
stead Research Ethics Committee; reference 10/
H0721/79) and local site approvals were obtained for
those scans performed as part of ATTRact-AS. Quan-
tification of scans performed clinically outside of
ATTRact-AS (n ¼ 39) was approved locally as a quality
improvement project at Barts Heart Centre (ID 9924).
Diagnostic work-up was performed at the National
Amyloidosis Centre in the majority of patients (70%).
DPD SCINTIGRAPHY. All DPD scans were performed
by using either a hybrid SPECT/CT gamma camera
(BrightView, Philips Healthcare, Amsterdam, the
Netherlands) or a SPECT gamma camera (Symbia,
Siemens Healthineers, Erlangen, Germany) following
the injection of w700 MBq DPD.The imaging protocol involved an early (5 min) and
late (3 h) planar whole-body image, with a SPECT/CT
or SPECT only scan of the chest at 3 h. If a CT scan was
not performed in the same sitting, then a contempo-
rary CT scan of the chest was used for attenuation
correction and SUV analysis (n ¼ 9 patients). DPD
scans were reported by 2 experienced clinicians using
the Perugini grading system (6), with grade 0 being
negative and grades 1 to 3 increasingly positive.
Planar whole-body scans were performed at a scan
speed of 20 cm/min; the matrix size was 256  1,024
on the Siemens Symbia and 512  1,024 on the Philips
BrightView. SPECT acquisitions used a contoured
orbit with 120 views in a 360 orbit, with 20 s per view
and a matrix size of 128  128. CT acquisitions of the
chest (performed as part of the SPECT/CT imaging)
were low dose, ungated, free-breathing, and
noncontrast.
SUV QUANTIFICATION. SPECT/CT acquisitions of
the chest were reconstructed by using Hybrid Recon
TABLE 1 Summary of Basic Patient Demographics, With a Breakdown of SUVpeak, Conventional Planar Quantification, and Heart/CL Ratio
Results by DPD Perugini Grade
Grade 0 (n ¼ 40) Grade 1 (n ¼ 12) Grade 2 (n ¼ 41) Grade 3 (n ¼ 7) p Value
Demographic characteristics
Male 12 (30) 9 (75) 27 (66) 4 (57) 0.003
Age 86  5 83  12 82  10 80  8 0.11
Amyloid type*
Likely wild-type ATTR – 9 (82) 24 (66) 1 (17) 0.03
Variant ATTR – 0 (0) 11 (31) 5 (83) 0.001
AL amyloid – 2 (18) 1 (3) 0 (0) 0.14
SUVpeak
Cardiac 1.0  0.4 3.7  1.5 11.9  3.8 10.6  1.5 <0.001
Paraspinal 0.6  0.1 0.9  0.2 1.0  0.3 1.3  0.3 <0.001
Vertebral 8.4  1.5 7.2  1.2 6.2  1.9 4.6  0.17 <0.001
Hepatic 0.6  0.2 0.6  0.2 0.6  0.3 0.5  0.2 0.87
SUV retention index 0.07  0.03 0.48  0.28 2.04  0.82 3.24  1.04 <0.001
Conventional planar
Heart retention 74.5  7.8 81.2  6.6 83.2  7.0 90.3  4.6 <0.001
WB retention 3.6  0.8 4.6  0.9 6.0  1.4 6.7  0.9 <0.001
Heart/WB ratio 4.9  0.9 5.7  0.9 7.2  1.6 7.4  1.1 <0.001
Heart/CL lung H/CL ratio 1.01  0.10 1.35  0.21 2.23  0.55 2.12  0.59 <0.001
Values are n (%) or mean  SD. *7 patients were excluded due to no diagnostic work-up results being available at the time of submission; percentages quoted reflect this.
Transthyretin genotyping was available in 70% of the transthyretin-related cardiac amyloidosis (ATTR-CA) population. Bold values p value <0.05.
H/CL ¼ heart/contralateral lung; DPD ¼ 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid; SUVpeak ¼ peak standardized uptake value; WB ¼ whole-body.
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Injected dose, residual dose, height, weight, and
timing data were inputted, and recorded counts per
voxel were converted into activity per unit volume
and then displayed as an SUV (a parameter repre-
senting the concentration of the radiopharmaceutical
in the respective tissue). Three-dimensional volumes
of interest (VOIs) were placed over the heart, adja-
cent vertebra, paraspinal muscle, and liver, and peak
SUV was recorded (Figure 1). Peak SUV is the highest
average SUV within a 1 cm3 volume. Care was taken
to avoid severe degenerative tracer uptake in the
vertebra when placing the relevant VOI.
The exploratory composite parameter of SUV
retention index was calculated as: (cardiac peak SUV/
vertebral peak SUV)  paraspinal muscle peak SUV.
CONVENTIONAL PLANAR QUANTIFICATION. Heart and
whole-body retention, as well as heart/whole-body
ratio were calculated by comparing regions of inter-
est (ROIs) placed over the heart, kidneys, and bladder
on the early and late planar DPD images, as described
by Perugini et al. (6).
H/CL RATIO QUANTIFICATION. A two-dimensional
ROI was placed over the heart and then mirrored
onto the contralateral lung on the late anterior whole-
body planar images (acquired 3 h post-DPD tracer
injection) (Figure 1). Mean counts per pixel were
recorded for each ROI. As per the American Society ofNuclear Cardiology practice points for PYP scintig-
raphy (11), the H/CL ratio was calculated as the mean
counts per pixel in the cardiac ROI divided by the
same in the contralateral lung ROI.
EXTRACELLULAR VOLUME QUANTIFICATION BY CT.
All CT scans were performed on a Somatom FORCE
scanner (Siemens Healthineers, Erlangen, Germany).
The technique for ECV quantification has been
described elsewhere (20); additional pre-contrast and
3-min post-contrast datasets were acquired. These
datasets were averaged, subtracted to provide a
partition coefficient, and then co-registered with the
CT coronary angiogram images. The patient’s he-
matocrit measurement (usually taken on the same
day) was inputted, and the myocardial ECV was
calculated as follows: ECVCT ¼ (1  hematocrit) 
(DHUmyo /DHUblood), where DHU is the change in
Hounsfield unit attenuation pre- and post-contrast
(i.e., HUpost-contrast  HUpre-contrast) (17–21).
STATISTICAL ANALYSIS. Statistical analysis was
performed using IBM SPSS Statistics version 25
(IBM SPSS Statistics, IBM Corporation, Armonk,
New York). Where appropriate, results are described
as mean  SD or median (interquartile range).
Kruskal-Wallis analysis of variance was used when
comparing more than 2 groups as the omnibus
test, with the Dunn-Bonferroni test for pairwise
comparison. Receiver-operating characteristic curve
FIGURE 2 Trends in SPECT/CT Quantification by DPD Perugini Grade
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Box and whisker plots illustrating the trend seen with increasing 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) Perugini grade in SUVpeak in
the heart (A), vertebra (B), paraspinal muscle (C), and the composite SUV retention index (D). Whisker lengths extend to 1.5 times the box height, or if no
case has a value in that range, to the minimum and maximum. Dots represent outliers. Abbreviations as in Figure 1.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 1 3 , N O . 6 , 2 0 2 0 Scully et al.
J U N E 2 0 2 0 : 1 3 5 3 – 6 3 DPD Quantification in Cardiac Amyloidosis
1357analysis was performed to assess diagnostic
performance. The Fisher exact test was used for
categorical data, Spearman’s rank-order correlation
was used to assess correlation, and the DeLong test
was used to compare areas under the curves.
A 2-sided p value <0.05 was considered statistically
significant.RESULTS
Analysis was performed on the DPD scans of 100 pa-
tients (mean age 84  9 years; 52% male), of which
forty were grade 0, twelve were grade 1, forty-one
were grade 2, and seven were grade 3. All patients
were identified retrospectively and selected for their
FIGURE 3 Diagnostic Accuracy for the Detection of Cardiac Amyloid
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Receiver-operating characteristic curves for the detection of cardiac amyloidosis using
the different methods of quantification of 99mTc-3,3-diphosphono-1,2-
propanodicarboxylic acid scintigraphy. Values in parentheses represent 95% confidence
intervals. AUC ¼ area under the curve; other abbreviations as in Figure 1.
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1358DPD result; therefore, this is not a prevalence study.
The average injected dose was 731  26 MBq. There
was a higher proportion of male patients in the DPD-
positive cohorts, likely reflecting referral bias.
Thirty-four patients with a positive DPD scan were
diagnosed with likely wild-type ATTR, 16 with variant
ATTR (thirteen V122I, one ApoA1, one E89Q, and one
I107V), and three with AL amyloid (the remaining
seven patients either declined or were awaiting
further investigation). TTR genotyping was available
for 40 (70%) of the 57 patients with suspected ATTR
cardiac amyloidosis. Two out of three patients with
AL amyloid had a grade 1 DPD scan.
PERUGINI PLANAR QUANTIFICATION. Heart, whole-
body retention, and heart/whole-body ratio increased
with increasing DPD grade (p < 0.001 for trend)
(Table 1). Pairwise comparison revealed a significant
difference between grades 0 and 2 and between
grades 0 and 3 only for all of these parameters.H/CL RATIO. The H/CL ratio increased from grade
0 to grade 2 and then plateaued between grades 2 and
3 (p < 0.001 for trend). Pairwise comparison revealed
a significant difference between all grades, except
between grades 1 and 3 (p ¼ 0.410) and grades 2 and 3
(p ¼ 1.000).
There was no significant difference in H/CL ratio in
those patients with a grade 1 DPD scan between the 2
patients with cardiac AL versus those with ATTR
(p ¼ 0.83).
SPECT/CT QUANTIFICATION. Cardiac peak SUV
increased from DPD Perugini grade 0 to grade 2; how-
ever, it plateaued between grades 2 and 3 (p<0.001 for
trend) (Table 1, Figure 2). Pairwise comparison
revealed a significant difference between all grades
except 1 and 3 (p ¼ 0.460) and 2 and 3 (p ¼ 1.000).
Paraspinal muscle peak SUV increased from grade 0 to
3 (p< 0.001 for trend), whereas vertebral peak SUV did
the opposite (p < 0.001 for trend). There was no dif-
ference in hepatic peak SUV between grades (p¼ 0.870
for trend).
The composite parameter of SUV retention index
helped overcome the plateauing of the cardiac peak
SUV between grades 2 and 3, increasing across all
grades (p < 0.001 for trend) (Table 1, Figure 2). Pair-
wise comparison showed a significant difference be-
tween all grades except 2 and 3 (p ¼ 1.000).
There was no significant difference between the 2
patients with cardiac AL and a grade 1 DPD scan and
those with ATTR in the same group in terms of cardiac
peak SUV (p ¼ 0.260) or SUV retention index
(p ¼ 0.970).
COMPARISON BETWEEN PLANAR AND SPECT/CT
QUANTIFICATION. The diagnostic accuracy for the
detection of any cardiac amyloid was excellent for
cardiac peak SUV, with an AUC of 0.999 (0.996 to
1.000), with a cutoff of >1.7 giving a sensitivity of
100% and a specificity of 75% (Figure 3). The SUV
retention index performed similarly well with an AUC
of 0.999 (0.997 to 1.000), and a cutoff of >0.14 pro-
vided the same sensitivity and specificity (p ¼ 0.480
for comparison with cardiac SUV peak).
In terms of planar quantification techniques, the H/
CL ratio performed the bestwith anAUCof 0.987 (0.966
to 1.000),with a ratio>0.97 giving a sensitivity of 100%
but a specificity of only 38% (p ¼ 0.270 and 0.250 for
comparison with cardiac peak SUV and SUV retention
index, respectively). The conventional heart and
whole-body retention, aswell as the heart/whole-body
ratio, did not perform as well as the cardiac peak SUV,
SUV retention index, or H/CL ratio (p < 0.050 for all),
with AUCs of 0.916 (0.858 to 0.974), 0.803 (0.715 to
0.892), and 0.869 (0.800 to 0.939) (Figure 3).
FIGURE 4 Correlation Between SPECT/CT Quantification and ECV Quantification by CT
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Scatter plot of cardiac SUVpeak against myocardial extracellular volume quantification
(ECV) by computed tomography (CT), showing good correlation across DPD Perugini
grades 0 to 2. Abbreviations as in Figures 1 and 2.
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1359REPRODUCIBILITY AND VARIABILITY. SPECT/CT quanti-
fication was repeated for 10 patients (three Perugini
grade 3, two grade 1, three grade 2, and two grade 3)
by the same reporter (P.R.S.) in a separate sitting,
blinded to the first set of results. In total, 50 param-
eters were assessed (cardiac, vertebral, hepatic, and
paraspinal muscle peak SUV, as well as the SUV
retention index for each patient). The mean differ-
ence in SUV across all measurements (repeat minus
initial measurement) was minimal at 0.01  0.38.
Importantly, looking at just the cardiac peak SUV
(n ¼ 10 measurements), the mean difference
remained small at 0.11  0.37. The intraclass correla-
tion coefficient (two-way, mixed effects model, ab-
solute agreement) for all 50 parameters was excellent
at 0.997 (95% CI: 0.994 to 0.998) for single measures.
Comparing the intraobserver variability for H/CL
ratio for the same 10 patients, there was minimal
mean difference between the results at 0.03  0.11.
The intraclass correlation coefficient (2-way, mixed
effects model, absolute agreement) was very good at
0.993 (95% CI: 0.972 to 0.998) for single measures.
Interobserver variability was also assessed for
SPECT/CT quantification and H/CL ratio in 5 patients
by a second reporter (K.P.P.), who was blinded to the
initial results. The mean difference in SUV across all
measurements (K.P.P. minus P.R.S.; 25 measure-
ments) remained small at –0.17  0.71. For cardiac
peak SUV alone (5 measurements) this difference was
–0.11  0.20. The intraclass correlation coefficient
(2-way, mixed effects model, absolute agreement)
for all 25 parameters was excellent at 0.989 (95% CI:
0.975 to 0.995) for single measures.
Looking only at the H/CL ratio for the same 5 pa-
tients, the mean difference (K.P.P. minus P.R.S.) was
0.05  0.11. The intraclass correlation coefficient
(2-way, mixed effects model, absolute agreement)
was excellent at 0.994 (95% CI: 0.954 to 0.999) for
single measures.
COMPARISON BETWEEN SPECT/CT QUANTIFICATION
AND ECV QUANTIFICATION BY CT. In a subgroup of
patients (n ¼ 44; mean age 87  5 years; 41% male),
comparison was made between cardiac peak SUV and
ECVCT. All patients had severe aortic stenosis: left
ventricular ejection fraction 57  8%, peak aortic
valve velocity 4.25  0.63 m/s, mean gradient 44 
14 mm Hg, and aortic valve area 0.67  0.21 cm2.
Twenty-nine patients were DPD Perugini grade 0, five
were grade 1, and ten were grade 2. Cardiac peak SUV
increased across the grades as seen in the overall
cohort (p < 0.001 for trend). Myocardial ECVCT
increased from 31  3% (grade 0) to 34  4% (grade 1)
to 44  5% (grade 2) (p < 0.001 for trend). There wasgood correlation between the increases in cardiac
peak SUV and ECVCT (r2 ¼ 0.73; p < 0.001) (Figure 4).
DISCUSSION
In terms of diagnostic accuracy, SPECT/CT quantifi-
cation of DPD scintigraphy using either cardiac peak
SUV or the composite SUV retention index was
exceptional and outperformed planar quantification
techniques. It is a simple tool that can help the
reporting clinician in making a diagnosis of cardiac
amyloidosis, particularly in subtle cases. In centers
where SPECT/CT is not available, the H/CL ratio is a
viable alternative quantification technique that per-
forms well and with a diagnostic accuracy similar to
that seen for the diagnosis of ATTR-CA in the PYP
literature (AUC 0.987 vs. 0.960 to 0.992) (12,13).
Although well established in PYP reporting, further
research is needed to validate the role of the H/CL
ratio in DPD (e.g., prognostic thresholds, imaging
time points [1 vs. 3 h], how results compare between
cardiac AL and ATTR). Conventional planar quantifi-
cation using heart and whole-body retention, as well
as heart/whole-body ratio, did not perform as well; as
a result, we have moved away from using these in our
clinical practice, obviating the need for the early
planar images-improving patient experience and
departmental workflow.
In terms of quantifying cardiac amyloid burden, it
is apparent that there is a huge spectrum of disease
FIGURE 5 The Unappreciated Spectrum of Disease
SUVpeak= 5.26 SUVpeak= 16.19 SUVpeak= 21.03
20
0
Planar images from three patients all demonstrating Perugini grade 2 cardiac uptake with some long bone suppression. The cardiac peak
standardized uptake value (peak SUV) is markedly different between patients, illustrating the wide range of cardiac involvement that is not
apparent or appreciated on planar imaging alone.
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1360that is not captured in the Perugini grading system
(perhaps unsurprising, given there are only 3 grades
of positivity used to describe a complex, multisystem
disorder) (6). An example of this is the variation in
cardiac peak SUV seen between patients with a grade2 DPD scan, which can range from 5 to 21 (Figure 5).
This grading system alone is unlikely to prove suffi-
ciently sensitive to facilitate the monitoring of
response (or lack thereof) to amyloid therapies in the
future. Unfortunately, what is also apparent is that
CENTRAL ILLUSTRATION Planar and SPECT/CT Quantification in DPD Scintigraphy
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Scully, P.R. et al. J Am Coll Cardiol Img. 2020;13(6):1353–63.
Planar and single-photon emission computed tomography/computed tomography (SPECT/CT) quantification was performed retrospectively on 100 99mTc-3,3-
diphosphono-1,2-propanodicarboxylic acid (DPD) scans. SPECT/CT quantification outperformed planar quantification and correlated with extracellular volume
quantification by computed tomography (ECVCT). Differentiation of Perugini grade 2 and 3 was confounded by soft tissue uptake, which may be overcome by using a
composite standardized uptake value (SUV) retention index, providing a potential novel biomarker for monitoring.
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1361quantification of cardiac amyloid burden at higher
Perugini grades is confounded by competition for the
radiotracer from surrounding soft tissue, resulting in
little detectable difference between grades 2 and 3
using cardiac peak SUV alone or H/CL ratio. This
makes sense given that this increased soft tissue up-
take is the reason for the “mild/absent bone uptake”
that forms part of the definition of a grade 3 DPD (6).
This is further supported by the increasing paraspinal
and reducing vertebral peak SUV seen across all
grades. This means that a direct measure of cardiac
uptake alone is unlikely to prove sufficient, reflecting
the complexity of the condition we are dealing
with. This being said, it is reassuring that cardiac peak
SUV tracked amyloid burden up to grade 2 as
measured by ECVCT, given that we already know that
cardiovascular magnetic resonance–derived ECV candetect disease regression with therapy in cardiac AL
amyloid (22) and also carries prognostic significance
in both ATTR-CA (23) and cardiac AL amyloid (24).
This would suggest that cardiac peak SUV (or, in turn,
the derived SUV retention index) may be used to
monitor amyloid regression and be associated with
prognosis. Further validation is clearly warranted,
particularly outside of the elderly population with
aortic stenosis studied here, in which the variation in
ECV in those without cardiac amyloid is likely to be
much less, and therefore the correlation may well
prove even better with cardiac peak SUV. Finally,
whether these parameters will also track blood
biomarkers (e.g., N-terminal pro–B-type natriuretic
peptide, troponin T) or predict heart failure hospi-
talizations is beyond the scope of the current paper
but merits investigation.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
SPECT/CT quantification of DPD outperforms con-
ventional planar quantification techniques and is a
potential tool for diagnosis and therapy monitoring in
cardiac amyloidosis.
TRANSLATIONAL OUTLOOK 1: SUV retention in-
dex is likely to prove a useful imaging biomarker in
future trials assessing amyloid-specific therapies.
TRANSLATIONAL OUTLOOK 2: Further research
is needed to investigate the prognostic significance of
the direct measurement of amyloid burden in those
undergoing DPD scintigraphy.
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1362The composite SUV retention index tries to account
for the competition for the DPD from both the
vertebra and the paraspinal muscle and perhaps of-
fers a means of better quantifying the amyloid
burden, which is otherwise apparent on the planar
images (Central Illustration). Further validation in
larger, multicenter studies is needed; however, it
could serve as a potential imaging biomarker of
response to therapy in upcoming and ongoing clinical
trials. Further research is also needed on the role it
may offer in differentiating cardiac-AL from ATTR-
CA, one of the holy grails of cardiac amyloid imaging.
STUDY LIMITATIONS. The range of patients reported
reflects the clinical practice of a large tertiary cardiac
center; however, there were relatively small
numbers of DPD Perugini grade 1 and grade 3 pa-
tients, which is likely to have effected our results. We
also only included 3 patients with AL amyloid,
meaning any conclusions drawn primarily relate to
the ATTR-CA population. ECVCT was only performed
in the subgroup of elderly patients with severe aortic
stenosis and, as a result, patients without cardiac
amyloid exhibited significant variation in ECVCT; this
is likely to affect the correlation with cardiac peak
SUV, which may well prove even better outside of
this population.
CONCLUSIONS
SPECT/CT quantification in DPD scintigraphy is
possible and outperforms planar quantificationtechniques. Differentiation of Perugini grade 2 or 3 is
confounded by soft tissue uptake, which can be
overcome by using a composite SUV retention index.
This index can help in the diagnosis of cardiac
amyloidosis and may offer a means of monitoring
response to therapy.
ADDRESS FOR CORRESPONDENCE: Dr. Leon J.
Menezes, Barts Heart Centre, St. Bartholomew’s
Hospital, West Smithfield, London EC1A 7BE, United
Kingdom. E-mail: leon.menezes@nhs.net.RE F E RENCE S1. Banypersad SM, Moon JC, Whelan C,
Hawkins PN, Wechalekar AD. Updates in cardiac
amyloidosis: a review. J Am Heart Assoc 2012;1:
e000364.
2. Scully PR, Treibel TA, Fontana M, et al. Preva-
lence of Cardiac Amyloidosis in Patients Referred
for Transcatheter Aortic Valve Replacement. J Am
Coll Cardiol 2018;71:463–4.
3. Castaño A, Narotsky DL, Hamid N, et al.
Unveiling transthyretin cardiac amyloidosis and
its predictors among elderly patients with severe
aortic stenosis undergoing transcatheter aortic
valve replacement. Eur Heart J 2017;38:
2879–87.
4. González-López E, Gallego-Delgado M, Guzzo-
Merello G, et al. Wild-type transthyretin
amyloidosis as a cause of heart failure with pre-
served ejection fraction. Eur Heart J 2015;36:
2585–94.
5. Gillmore JD, Maurer MS, Falk RH, et al. Non-
biopsy diagnosis of cardiac transthyretin
amyloidosis. Circulation 2016;133:2404–12.
6. Perugini E, Guidalotti PL, Salvi F, et al. Noninva-
sive etiologic diagnosis of cardiac amyloidosis using99mTc-3,3-diphosphono-1,2-propanodicarboxylic
acid scintigraphy. J Am Coll Cardiol 2005;46:
1076–84.
7. Hutt DF, Fontana M, Burniston M, et al. Prog-
nostic utility of the Perugini grading of 99mTc-
DPD scintigraphy in transthyretin (ATTR)
amyloidosis and its relationship with skeletal
muscle and soft tissue amyloid. Eur Heart J Car-
diovasc Imaging 2017;18:1344–50.
8. Maurer MS, Schwartz JH, Gundapaneni B, et al.
Tafamidis treatment for patients with trans-
thyretin amyloid cardiomyopathy. N Engl J Med
2018;379:1007–16.
9. Solomon SD, Adams D, Kristen A, et al. Effects
of patisiran, an RNA interference therapeutic, on
cardiac parameters in patients with hereditary
transthyretin-mediated amyloidosis: analysis
of the APOLLO Study. Circulation 2019;139:
431–43.
10. Dasgupta NR, Benson M. Improved survival
of patients with transthyretin amyloid cardio-
myopathy with Inotersen (TTR specific anti-
sense oligonucleotide). J Am Coll Cardiol 2019;
73:811.11. Dorbala S, Bokhari S, Miller E, Bullock-Palmer R,
Soman P, Thompson R. 99mTechnetium-pyrophos-
phate imaging for transthyretin cardiac amyloidosis
2019. ASNC Practice Points: 99mTechnetium-Pyro-
phosphate Imaging for Transthyretin Cardiac
Amyloidosis. Available at: https://www.asnc.org/
Files/Amyloid/ASNC%20Practice%20Point-99m
Technetium-Pyrophosphate.2019.pdf. Accessed
May 8, 2020.
12. Bokhari S, Castaño A, Pozniakoff T, Deslisle S,
Latif F, Maurer MS. 99mTc-pyrophosphate scintig-
raphy for differentiating light-chain cardiac
amyloidosis from the transthyretin-related familial
and senile cardiac amyloidoses. Circ Cardiovasc
Imaging 2013;6:195–201.
13. Castano A, Haq M, Narotsky DL, et al. Multi-
center study of planar technetium 99m pyro-
phosphate cardiac imaging: predicting survival for
patients with ATTR cardiac amyloidosis. JAMA
Cardiol 2016;1:880–9.
14. Soderlund TA, Dickson JC, Prvulovich E, et al.
Value of semiquantitative analysis for clinical
reporting of 123I-2-b-carbomethoxy-3b-(4-
iodophenyl)-N-(3-fluoropropyl)nortropane SPECT
studies. J Nucl Med 2013;54:714–22.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 1 3 , N O . 6 , 2 0 2 0 Scully et al.
J U N E 2 0 2 0 : 1 3 5 3 – 6 3 DPD Quantification in Cardiac Amyloidosis
136315. Dewaraja YK, Schipper MJ, Roberson PL, et al.
131I-tositumomab radioimmunotherapy: initial tu-
mor dose-response results using 3-dimensional
dosimetry including radiobiologic modeling.
J Nucl Med 2010;51:1155–62.
16. Sado DM, Flett AS, Banypersad SM, et al.
Cardiovascular magnetic resonance measurement
of myocardial extracellular volume in health and
disease. Heart 2012;98:1436–41.
17. Treibel TA, Bandula S, Fontana M, et al.
Extracellular volume quantification by dynamic
equilibrium cardiac computed tomography in car-
diac amyloidosis. J Cardiovasc Comput Tomogr
2015;9:585–92.
18. Nacif MS, Kawel N, Lee JJ, et al. Interstitial
myocardial fibrosis assessed as extracellularvolume fraction with low-radiation-dose cardiac
CT. Radiology 2012;264:876–83.
19. Bandula S, White SK, Flett AS, et al. Mea-
surement of myocardial extracellular volume
fraction by using equilibrium contrast-enhanced
CT: validation against histologic findings. Radi-
ology 2013;269:396–403.
20. Scully PR, Treibel TA, Klotz E, et al. 24Amy-
loid-AS: detecting occult Cardiac Amyloid during
TAVI work-up computed tomography. Eur Heart J
Cardiovasc Imaging 2019;20.
21. Nacif MS, Liu Y, Yao J, et al. 3D Left ventricular
extracellular volume fraction by low-radiation
dose cardiac CT: assessment of interstitial
myocardial fibrosis. J Cardiovasc Comput Tomogr
2013;7:51–7.22. Martinez-Naharro A, Abdel-Gadir A,
Treibel TA, et al. CMR-verified regression of car-
diac AL amyloid after chemotherapy. J Am Coll
Cardiol Img 2018;11:152–4.
23. Martinez-Naharro A, Kotecha T, Norrington K,
et al. Native T1 and extracellular volume in
transthyretin amyloidosis. J Am Coll Cardiol Img
2019;12:810–9.
24. Banypersad SM, Fontana M, Maestrini V, et al.
T1 mapping and survival in systemic light-chain
amyloidosis. Eur Heart J 2015;36:244–51.KEY WORDS cardiac amyloidosis, DPD
scintigraphy, SPECT/CT quantification
